Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology
Each subsidiary may utilize the CPB platform capabilities to commercialize products independently or through strategic collaborations. The subsidiaries’ diverse product pipeline mitigates the risk associated with individual development and drive opportunities forward.
Human Microbiome
Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology
Immuno-oncology
Readout & completion of POC from first in-human study; Pre-IND meeting with FDA
IBD
Clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA
IBS
Advancement of pre-clinical studies and nomination of bacterial consortium for clinical trial
Ag Biologicals
Lavie Bio Mission: Improve food quality, sustainability and agriculture productivity through
microbiome based ag-biologicals technology and products
Bio-stimulants
Thrivus™ – distribution licensing agreements and sales expansion in USA & Canada. Expansion to additional crops and an additional territory in 2025
Bio-pesticides
US regulatory approval for bio-fungicide candidate for fruit rots (LAV311) – expected by 2024
Submission for Lavie Bio’s bio-fungicide candidate for downy mildew (LAV321) to the US EPA for regulatory approval – expected by 2024
Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company – expected by 2024
Ag-Chemicals
AgPlenus Mission: Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology
Herbicides
Milestone achievement of the ongoing collaboration with Corteva
Engage in a new additional strategic collaboration
Fungicides
Nominate new Mode-of-Action protein targets
Initial greenhouse readouts of designed compounds on the defined fungi targets
Platform
Verification of computational tool for selection of novel Mode-of-Action protein targets
POC for the computational tool for novel molecule design
Medical Cannabis
Canonic Mission: Provide tailored medical cannabis products to optimize consumer wellbeing
Direct sales
Increased revenues from the 2nd generation products during 2023
Launch of 3rd generation products with high THC levels, specific terpene profiles and unique characteristics, towards end of 2023
New revenue streams
Commence joint production of Canonic’s varieties with a 3rd party based on cost and revenue sharing
Royalties from licensing of Canonic’s varieties
Castor Oil Production
Castera Mission: Leading the castor oil market with an integrated solution for industrialized cultivation of castor in support of the biobased materials industry
Seeds development
Production – extending production outreach in the target markets: Africa (Zambia), Latin America (Brazil) with few hundred tons a year as of 2024
R&D – development of new seed traits matching industry needs (e.g., Ricin free, low viscosity) using advanced technologies: CRISPR, genetic markers
Territorial expansion
Africa - engaging with bio-fuel strategic industry leaders to increase our sales and sector footprint
Latin America – addressing the bio-polymer industry’s interest in broad, consistent and high-quality castor oil supply in Latin America
Strategic alliance
A strategic alliance with a leading global biofuel company, leveraging Casterra’s holistic industrial solution